Allogene Therapeutics Proposes $175 Million Public Offering of Common Stock
ALLO has more than doubled off its 52-week low of $0.862 on elevated volume (12× avg).
Summary
Allogene Therapeutics announced a proposed underwritten public offering of $175 million of its common stock, with an option for underwriters to purchase an additional $26.25 million. This significant capital raise, representing approximately 23.5% of the company's current market capitalization, follows earlier positive interim futility analysis results from its pivotal Phase 2 ALPHA3 trial reported today. While raising capital is a strategic move for a clinical-stage biotech, especially after positive data, the substantial dilution for existing shareholders is a material negative event. Traders will be watching for the pricing and completion of the offering, as well as the market's reaction to this significant dilution in the context of the recent positive clinical news.
At the time of this announcement, ALLO was trading at $2.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $744.7M. The 52-week trading range was $0.86 to $4.46. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.